Papers
2
Total Citations
53
H-Index
2
About
Robin Coope is a molecular diagnostics researcher whose work bridges clinical genomics and pandemic response. Their key contributions lie in hereditary cancer testing and high-throughput infectious disease detection. Coope’s most impactful work, a 2013 study on a clinically validated second-generation sequencing assay for hereditary *BRCA1* and *BRCA2* mutations (42 citations), established a robust diagnostic framework for identifying cancer-predisposing genetic variants. This assay has been instrumental in enabling accurate, scalable screening for patients at risk of breast and ovarian cancers. During the COVID-19 pandemic, Coope pivoted to address critical testing shortages. Their 2023 study on extraction-free SARS-CoV-2 detection from saline gargle samples using the Hamilton STARlet liquid handler (11 citations) demonstrated a rapid, cost-effective method that bypassed reagent bottlenecks. By optimizing self-collected samples and multiplex PCR workflows, this work directly supported high-throughput clinical testing, alleviating strain on overwhelmed laboratories. Coope’s research exemplifies translational impact—from advancing precision oncology to enabling agile pandemic diagnostics—showcasing a career dedicated to making molecular testing more accessible, efficient, and clinically actionable.
Research Focus
Key Achievements
Top Papers
- 1
- 2